Phase I/II study of oral administration of S 49076 given in combination with gefitinib in patients with EGFR mutated advanced non-small-cell lung cancer who have progressed after treatment with EGFR tyrosine kinase inhibitor.

Trial Profile

Phase I/II study of oral administration of S 49076 given in combination with gefitinib in patients with EGFR mutated advanced non-small-cell lung cancer who have progressed after treatment with EGFR tyrosine kinase inhibitor.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs S-49076 (Primary) ; Gefitinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors IRIS
  • Most Recent Events

    • 08 Sep 2017 According to trial design presented at 42nd European Society for Medical Oncology Congress, the end of phase I is expected in Q3 2017.
    • 08 Sep 2017 Trial design presented at 42nd European Society for Medical Oncology Congress.
    • 23 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top